

# C64

## Quantitative Measurement of Proteins and Peptides by Mass Spectrometry



This guideline describes the design, development, and validation of quantitative assays for proteins and peptides by mass spectrometry.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

## Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute

P: +1.610.688.0100

F: +1.610.688.0700

[www.clsi.org](http://www.clsi.org)

[standard@clsi.org](mailto:standard@clsi.org)

# Quantitative Measurement of Proteins and Peptides by Mass Spectrometry

Cory Bystrom, PhD  
Russell P. Grant, PhD  
Lorin M. Bachmann, PhD, DABCC, MT(ASCP)  
Mari DeMarco, PhD  
Daniel T. Holmes, MD, FRCPC  
Andrew N. Hoofnagle, MD, PhD  
Daniel Intelmann, PhD  
Doug Jeffery, PhD

Mark M. Kushnir, PhD  
Paula Ladwig, MS, MT(ASCP)  
Mark S. Lowenthal, PhD  
Stephen R. Master, MD, PhD  
Christopher M. Shuford, PhD  
Stefani Thomas, PhD, NRCC  
Jeffrey Whiteaker, PhD

## Abstract

Clinical and Laboratory Standards Institute guideline C64—*Quantitative Measurement of Proteins and Peptides by Mass Spectrometry* provides a framework for developing clinical protein and peptide assays from conception to validation. This guideline is intended for those who have experience with traditional small-molecule liquid chromatography–mass spectrometry (LC-MS) but not with protein and peptide analysis. Although closely related to traditional small-molecule analysis by LC-MS, protein and peptide analysis involves unique challenges and necessitates complex workflows, which are covered in detail. To enhance translation of assays to clinical use, this guideline focuses on method development aligned with clinically appropriate analytical validation.

Clinical and Laboratory Standards Institute (CLSI). *Quantitative Measurement of Proteins and Peptides by Mass Spectrometry*. 1st ed. CLSI guideline C64 (ISBN 978-1-68440-110-9 [Print]; ISBN 978-1-68440-111-6 [Electronic]). Clinical and Laboratory Standards Institute, USA, 2021.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org).

**If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at:**

**P:** +1.610.688.0100 **F:** +1.610.688.0700 **E:** [customerservice@clsi.org](mailto:customerservice@clsi.org) **W:** [www.clsi.org](http://www.clsi.org)

Copyright ©2021 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, derivative product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

## Suggested Citation

CLSI. *Quantitative Measurement of Proteins and Peptides by Mass Spectrometry*. 1st ed. CLSI guideline C64. Clinical and Laboratory Standards Institute; 2021.

C64-Ed1

ISBN 978-1-68440-110-9 (Print)

ISBN 978-1-68440-111-6 (Electronic)

ISSN 1558-6502 (Print)

ISSN 2162-2914 (Electronic)

Volume 41, Number 6

.....

## Committee Membership

### Consensus Council

**James R. Petisce, PhD**  
**Chairholder**  
**BD Diagnostic Systems**  
 USA

Avis Danishefsky, PhD  
 FDA Center for Devices and  
 Radiological Health  
 USA

M. Laura Parnas, PhD, DABCC  
 Roche Diagnostics  
 USA

**Tania Motschman, MS, MT(ASCP)SBB**  
**Vice-Chairholder**  
 USA

Collette Fitzgerald, PhD  
 Centers for Disease Control and  
 Prevention  
 USA

Victoria Petrides, MS  
 Abbott  
 USA

Deirdre Astin, MS, MT(ASCP)  
 USA

Michelle McLean, MS, MT(ASCP), BS  
 Greiner Bio-One, Inc.  
 USA

Matthew A. Wikler, MD, FIDSA, MBA  
 IDTD Consulting  
 USA

Anne T. Daley, MS, MT(ASCP)DLM,  
 CMQ/OE(ASQ)CSBB  
 USA

James H. Nichols, PhD, DABCC, FAACC  
 Vanderbilt University School of  
 Medicine  
 USA

### Document Development Committee on Quantitative Measurement of Proteins and Peptides by Mass Spectrometry

**Cory Bystrom, PhD**  
**Chairholder**  
**Cleveland HeartLab, LLC**  
 USA

Mark W. Duncan, PhD  
 Veritomyx Inc.  
 USA

Paula Ladwig, MS, MT(ASCP)  
 Mayo Clinic  
 USA

**Russell P. Grant, PhD**  
**Vice-Chairholder**  
**Laboratory Corporation of America,**  
**Inc.**  
 USA

Daniel T. Holmes, MD, FRCPC  
 St. Paul's Hospital  
 Canada

Mark S. Lowenthal, PhD  
 National Institute of Standards and  
 Technology  
 USA

Lorin M. Bachmann, PhD, DABCC,  
 MT(ASCP)  
 VCU Health System  
 USA

Andrew N. Hoofnagle, MD, PhD  
 University of Washington Medical  
 Center  
 USA

Stephen R. Master, MD, PhD  
 Children's Hospital of Philadelphia  
 USA

Doug Jeffery, PhD  
 FDA Center for Devices and  
 Radiological Health  
 USA

**Expert Panel on Clinical Chemistry and Toxicology**

**Lorin M. Bachmann, PhD, DABCC,  
MT(ASCP)  
Chairholder  
VCU Health System  
USA**

Johanna Camara, PhD  
National Institute of Standards and  
Technology  
USA

Richard Y. Wang, DO  
Centers for Disease Control and  
Prevention  
USA

**Kamisha Johnson-Davis, PhD, DABCC,  
FACB  
Vice-Chairholder  
ARUP Laboratories  
USA**

Theodore J. DiMagno, PhD  
Ortho Clinical Diagnostics, Inc.  
USA

Carl E. Wolf, PhD, MS, F-ABFT  
VCU Health System  
USA

David Alter, MD  
Emory University Hospital  
USA

Marianela Perez-Torres, MT, PhD  
FDA Center for Devices and  
Radiological Health  
USA

Ronald Booth, PhD, FCACB, FACC  
The Ottawa Hospital  
Canada

Daniel Schwanzar  
Phadia GmbH  
Germany

**Staff**

Clinical and Laboratory Standards  
Institute  
USA

Megan L. Tertel, MA, ELS  
*Editorial Manager*

Kristy L. Leirer, MS  
*Editor*

Nisha Fernandes, MS, MBA  
*Project Manager*

Catherine E.M. Jenkins, ELS  
*Editor*

Laura Martin  
*Editor*

## Acknowledgment

CLSI, the Consensus Council, and the Document Development Committee on Quantitative Measurement of Proteins and Peptides by Mass Spectrometry gratefully acknowledge the following volunteers for their important contributions to the development of this guideline:

Jennifer Powers Carson, PhD  
Washington University in St. Louis  
USA

Daniel Intelmann, PhD  
Roche Diagnostics GmbH  
Germany

Stefani Thomas, PhD, NRCC  
University of Minnesota  
USA

Donald Walt Chandler, PhD  
Laboratory Corporation of America,  
Inc.  
USA

Richard King  
PharmaCadence Analytical Services,  
LLC  
USA

Faye Vazvaei  
Merck & Co.  
USA

Tom Collier  
Valley Medical Center  
USA

Mark M. Kushnir, PhD  
ARUP Laboratories  
USA

Jeffrey Whiteaker, PhD  
Fred Hutchinson Cancer Research  
Center  
USA

Mari DeMarco, PhD  
St. Paul's Hospital  
Canada

Amanda G. Paulovich, MD, PhD  
Fred Hutchinson Cancer Research  
Center  
USA

Yan Victoria Zhang, PhD  
University of Rochester Medical  
Center  
USA

Ashley Beasley Green, PhD  
National Institute of Standards and  
Technology  
USA

Jesse C. Seegmiller, PhD  
University of Minnesota Medical  
Center, Fairview  
USA

Matthew Humbard, PhD  
FDA Center for Devices and  
Radiological Health  
USA

Christopher M. Shuford, PhD  
Laboratory Corporation of America, Inc.  
USA





# Contents

Abstract	i
Committee Membership	iii
Foreword	ix
<b>Chapter 1: Introduction</b>	<b>1</b>
1.1 Scope	2
1.2 Standard Precautions	2
1.3 Terminology	3
<b>Chapter 2: Path of Workflow</b>	<b>9</b>
<b>Chapter 3: Measurands</b>	<b>13</b>
3.1 Insulin-like Growth Factor 1	15
3.2 Thyroglobulin	15
3.3 Apolipoproteins	16
3.4 Glycated Hemoglobin	16
<b>Chapter 4: Workflows and Instrumentation</b>	<b>17</b>
4.1 Workflows	18
4.2 Instrumentation	21
<b>Chapter 5: Internal Standards</b>	<b>25</b>
5.1 Types, Molecular Forms, and Applications	26
5.2 Common Internal Standard Structural Motifs	27
5.3 Effective Use of Internal Standards	30
5.4 Order of Addition	31
5.5 Quality Considerations	32
<b>Chapter 6: Calibration</b>	<b>37</b>
6.1 Harmonization	38
6.2 Standardization	38
6.3 Approaches to Calibration	39
6.4 Errors in Calibration	40
6.5 Choice of Calibrator Matrix	41
6.6 Choice of Calibrant	42
6.7 Calibrator Qualification	43
6.8 Methods of Concentration Assignment	45
6.9 Calibration for Post-Translational Modifications	46
6.10 Practical Use for Routine Production	47

## Contents (Continued)

<b>Chapter 7: Assay Development</b> .....	<b>49</b>
7.1 Feasibility Determination and Planning .....	50
7.2 Definition of the Measurand .....	50
7.3 Empirical Optimization .....	54
7.4 Quality Control and Proficiency Testing Materials .....	67
7.5 Prevalidation Performance Evaluation .....	67
<b>Chapter 8: Validation</b> .....	<b>69</b>
8.1 General Considerations for Validation Planning .....	70
8.2 Imprecision and Reproducibility .....	71
8.3 Analytical Sensitivity: Lower Limit of the Measuring Interval .....	72
8.4 Linearity and Extended Measuring Intervals .....	73
8.5 Measurand Stability .....	74
8.6 Reagent Stability .....	74
8.7 Analytical Selectivity, Interferences, and Matrix Effect .....	74
8.8 Carryover .....	75
8.9 Quality Monitoring: Ion Transition Ratios .....	76
8.10 Accuracy, Trueness, and Method Comparison .....	76
8.11 Validation of Acceptable Sample Matrixes .....	78
8.12 Validation of the Clinical Cutoff .....	78
8.13 Ongoing Performance Monitoring .....	79
<b>Chapter 9: Conclusion</b> .....	<b>85</b>
<b>Chapter 10: Supplemental Information</b> .....	<b>87</b>
<b>References</b> .....	88
<b>The Quality Management System Approach</b> .....	100
<b>Related CLSI Reference Materials</b> .....	101

## Foreword

---

This guideline is intended to accompany CLSI documents C62<sup>1</sup> and EP19.<sup>2</sup> Many of the recommendations found in CLSI documents C62<sup>1</sup> and EP19<sup>2</sup> also apply to liquid chromatography–mass spectrometry (MS) protein measurements, and commonalities are highlighted. However, this guideline primarily concentrates on aspects that are unique to quantitative measurement of proteins and peptides by MS.

**NOTE:** The content of this guideline is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

### KEY WORDS

Assay development

Mass spectrometry

Surrogate peptide

Bioanalysis

Peptide

Validation

Liquid chromatography

Protein

This page is intentionally left blank.

.....

# Chapter 1

## Introduction

### This chapter includes:

- Guideline's scope and applicable exclusions
- Standard precautions information
- Terminology information, including:
  - Terms and definitions used in the guideline
  - Abbreviations and acronyms used in the guideline

# Quantitative Measurement of Proteins and Peptides by Mass Spectrometry

## 1 Introduction

### 1.1 Scope

This guideline provides broad recommendations for appropriately developing and validating quantitative protein and peptide assays for clinical applications using electrospray liquid chromatography–mass spectrometry (LC-MS) and liquid chromatography–tandem mass spectrometry (LC-MS/MS) techniques. C64 is practically focused and includes workflow overviews and experimental strategies for developing and validating quantitative assays for soluble proteins and peptides in biofluids (eg, serum, saliva, urine). It covers complex analyses, including measurement of proteins with post-translational modifications (PTMs). Although there are a diverse array of ionization modes and associated mass analyzers (eg, matrix-assisted laser desorption/ionization time-of-flight [MALDI-TOF] mass spectrometry [MS]), this guideline focuses on liquid chromatography (LC) and electrospray ionization (ESI) coupled with tandem mass spectrometry (MS/MS) because of the wide availability and proven utility of this method.

A protein or peptide associated with a medical diagnosis or clinical outcome may exist *in vivo* as a single specified molecular composition or as a complex collection of related proteoforms that differ in molecular composition. Given the heterogenous nature of proteins and the desirability of facilitating results standardization among different assays, the need to appropriately define the measurand is a key difference between small-molecule analysis and protein analysis. In order to design a suitable workflow for measurand assessment, the assay developer needs to consider analyte properties, enrichment and fractionation strategy, and instrument performance characteristics. Subsequently, calibrators and internal standards (IS) are selected based on the chosen workflow and a precisely defined measurand. At the beginning of method development, performance criteria guide the conception and refinement of the path of workflow. Following this iterative process, the developer eventually prepares a candidate method sufficiently robust to pass validation. Finally, rigorous validation studies are performed to demonstrate suitability for routine clinical use.

The intended users of this guideline are medical, research, and public health laboratories; *in vitro* diagnostic instrument manufacturers; and regulatory and accreditation organizations.

Tissues and other nonbiofluid specimens are not within this guideline's scope. Enzyme activity assays are also considered out of scope, as are detailed discussions of software tools and data processing algorithms used for *in silico* analysis of protein and peptide sequences.

### 1.2 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of all known infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of bloodborne pathogens. Published guidelines are available that discuss the daily operations of diagnostic medicine in humans and animals while encouraging a culture of safety in the laboratory.<sup>3</sup> For specific precautions for preventing the laboratory transmission of all known infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all known infectious diseases, refer to CLSI document M29.<sup>4</sup>